Home > Neurology > EAN 2022 > Multiple Sclerosis > When to start, switch, and stop MS therapy: Real-world evidence counts

When to start, switch, and stop MS therapy: Real-world evidence counts

Presented By
Prof. Melinda Magyari, Rigshospitalet, Denmark
Conference
EAN 2022
Doi
https://doi.org/10.55788/e415e30f
Real-world data provide supplementary information on: a) the importance of starting a disease-modifying therapy (DMT) early in multiple sclerosis (MS), b) on switching to high-efficacy DMT when moderate-efficacy DMT cannot stabilise the disease, and c) on starting high-efficacy DMT as first treatment, and stopping MS therapy in later stages of MS. Randomised-controlled trials may be the gold standard of evidence but real-world data provides important supplementary data on DMTs in MS. “Although real-world research lacks blinding and randomisation, it uses unselected populations of patients, under real circumstances, with very different lifestyles and comorbidities, and can follow them for a long time,” argued Prof. Melinda Magyari (Rigshospitalet, Denmark) [1]. Possible real-world data sources are disease registries, databases, administrative claim data, medical records, big data, and (hopefully in the future) wearable devices. A critical ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on